Sign inCreate account

Report workspace tools

NCT04611711UNKNOWNanonymous

An Evaluation of the Effectiveness and Safety of Decitabine Combined With TQB2450 Injection (PD-L1 Monoclonal Antibody) or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors I /Phase II Clinical Study

Sponsor

Source record

Peking University

Phase

Source record

Phase 1/2

Modality

AI-normalized

small molecule

Target

AI-normalized

PD-L1 (Programmed Death-Ligand 1), with additional focus on epigenetic modulation via decitabine and angiogenesis inhibition via anlotinib.

Indication / condition

AI-normalized

Patients With Digestive System Tumors Resistant to PD-1 Inhibitors

Intervention

Source record

decitabine＋ TQB2450 injection, decitabine＋ TQB2450 injection＋Anlotinib

Source & freshness

Source record

NCT ID

NCT04611711

Original source

ClinicalTrials.gov

Source last updated

Nov 02, 2020

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04611711

Title

An Evaluation of the Effectiveness and Safety of Decitabine Combined With TQB2450 Injection (PD-L1 Monoclonal Antibody) or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors I /Phase II Clinical Study

Sponsor

Peking University

Status

UNKNOWN

Phase

Phase 1/2

Condition raw

Patients With Digestive System Tumors Resistant to PD-1 Inhibitors

Condition normalized

Patients With Digestive System Tumors Resistant to PD-1 Inhibitors

Modality raw

small molecule

Modality normalized

small molecule

Target raw

PD-L1 (Programmed Death-Ligand 1), with additional focus on epigenetic modulation via decitabine and angiogenesis inhibition via anlotinib.

Target normalized

PD-L1 (Programmed Death-Ligand 1), with additional focus on epigenetic modulation via decitabine and angiogenesis inhibition via anlotinib.

Interventions

decitabine＋ TQB2450 injection, decitabine＋ TQB2450 injection＋Anlotinib

Public preview

Source record

This clinical trial, sponsored by Peking University, aims to evaluate the effectiveness and safety of a combination therapy involving decitabine, TQB2450 (a PD-L1 monoclonal antibody), and anlotinib in patients with digestive system tumors that have shown resistance to PD-1 inhibitors. The market for cancer therapies, particularly those targeting immune resistance mechanisms, is rapidly expanding, with significant competition from existing PD-1/PD-L1 inhibitors and emerging combination therapies. Successful outcomes could position the sponsor favorably within this competitive landscape, particularly if they demonstrate improved efficacy in a patient population with limited treatment options. Diligence should focus on the trial's recruitment status and the regulatory pathway for TQB2450, as well as potential partnerships for commercialization.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Evaluation of the Effectiveness and Safety of Decitabine Combined With TQB2450 Injection (PD-L1 Monoclonal Antibody) or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors I /Phase II Clinical Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04611711

Status

UNKNOWN

Phase

Phase 1/2

Sponsor

Peking University

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Peking University, aims to evaluate the effectiveness and safety of a combination therapy involving decitabine, TQB2450 (a PD-L1 monoclonal antibody), and anlotinib in patients with digestive system tumors that have shown resistance to PD-1 inhibitors. The market for cancer therapies, particularly those targeting immune resistance mechanisms, is rapidly expanding, with significant competition from existing PD-1/PD-L1 inhibitors and emerging combination therapies. Successful outcomes could position the sponsor favorably within this competitive landscape, particularly if they demonstrate improved efficacy in a patient population with limited treatment options. Diligence should focus on the trial's recruitment status and the regulatory pathway for TQB2450, as well as potential partnerships for commercialization.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 02, 2020
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04611711

Indication

Patients With Digestive System Tumors Resistant to PD-1 Inhibitors

Modality

small molecule

Target

PD-L1 (Programmed Death-Ligand 1), with additional focus on epigenetic modulation via decitabine and angiogenesis inhibition via anlotinib.

Intervention

decitabine＋ TQB2450 injection, decitabine＋ TQB2450 injection＋Anlotinib

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.